Our Story
Spectral AI is an artificial intelligence company focusing on medical diagnostics, predictive analytics, and ‘Day One’ healing predictions.
-
2013
Spectral AI Incorporated
-
2014
DeepView Generation 1 510(k) clearance
-
2015
First BARDA Contract
-
2016
DeepView Generation 2 (510k) clearance
-
2017
First Defense Health Agency Contract
-
2018
FDA Breakthrough Designation – Burn
-
2019
Burn Proof Concept Clinical Study Initiated
-
2020
DFU Proof of Concept Clinical Study Initiated
-
2021
Secondary BARDA Burn Contract
-
2021
Burn AI Training Study Initiated
-
2021
Admission to Trading on AIM London Exchange
-
2021
First Department of Defense Contract
-
2022
DFU Validation Study Initiated
-
2023
EU DFU Clinical Study Initiation
-
2023
Business Combination Agreement
-
2023
US Burn AI training Study Completed
-
2024
DeepView AI®-Burn obtains the final stage of UK Conformity Assessed (UKCA) authorisation, for aiding in burn wound diagnosis in the UK
-
2024
Spectral AI launches free educational webinar series on burn injury wound assessment and care management for UK healthcare professionals
-
2024
UK burns experts share their experiences of being the first in the world to evaluate DeepView® burn wound care technology
At The Forefront
of Innovation
Provides faster and more accurate treatment insight, significantly improving patient care and clinical outcomes.
Let’s Talk
Want to Learn More About Spectral AI, DeepView®, and our Team?